LUCD - Lucid Diagnostics In...

Valuation of Lucid Diagnostics Inc.(LUCD), Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The co

Lucid Diagnostics Inc.

LUCD

NASDAQ

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

0.799 USD

-0.0031 (-0.388%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

Valuation Date:

Apr 18, 2024 4:00 PM

Share Price on Valuation Date

$0.8

Stock Beta

1.625

Shares Outstanding

48244797

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.